Joint Clinical Assessment, JCA
Tarlatamab (SCLC)
Dossier assessment
Indication:
Treatment of extensive-stage small cell lung cancer (ESSCLC)
Press releases
First EU HTAs with IQWiG involvement launched
The Institute is involved in four oncology drug assessments as an assessor or co-assessor.
Timetable
- 2nd quarter, 2025
- Start
- 3rd quarter, 2026
- voraussichtlicher Abschluss
Project details
- Project no.
- MP-202417
- Report type
- Joint Clinical Assessment, JCA
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the NCPHP (National Centre for Public Health and Pharmacy) Hungary.
The joint clinical assessment will be published on the European Commission’s website: https://health.ec.europa.eu/publications/joint-clinical-assessment-report-tarlatamab-imdylltra_en
Further background information can be found here: European health technology assessment